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Pluripotent stem cells have distinct metabolic re-
quirements, and reprogramming cells to pluripo-
tency requires a shift from oxidative to glycolytic
metabolism. Here, we show that this shift occurs
early during reprogramming of human cells and
requires hypoxia-inducible factors (HIFs) in a stage-
specific manner. HIF1a and HIF2a are both neces-
sary to initiate this metabolic switch and for the
acquisition of pluripotency, and the stabilization of
either protein during early phases of reprogramming
is sufficient to induce the switch to glycolytic metab-
olism. In contrast, stabilization of HIF2a during later
stages represses reprogramming, partly because of
the upregulation of TNF-related apoptosis-inducing
ligand (TRAIL). TRAIL inhibits induced pluripotent
stem cell (iPSC) generation by repressing apoptotic
caspase 3 activity specifically in cells undergoing re-
programming but not human embryonic stem cells
(hESCs), and inhibiting TRAIL activity enhances
human iPSC generation. These results shed light on
the mechanisms underlying the metabolic shifts as-
sociated with the acquisition of a pluripotent identity
during reprogramming.
INTRODUCTION
In contrast to differentiated cells, human embryonic stem cells
(hESCs) rely mainly on glycolysis for their source of energy, re-
gardless of oxygen availability (Folmes et al., 2011; Panopoulos
et al., 2012; Prigione and Adjaye, 2010; Varumet al., 2011; Zhang
et al., 2011; Zhou et al., 2012). Pluripotent cells share this meta-
bolic particularity with cancer cells (Warburg effect) (Cairns et al.,
2011). In both cell types, glycolytic genes are upregulated, mito-
chondrial activity is reduced, and lactate production is signifi-
cantly increased (Panopoulos et al., 2012; Prigione et al., 2010;592 Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc.Varum et al., 2011; Yanes et al., 2010). Furthermore, it has
recently been proposed that the metabolic properties of stem
cells and cancer cells are important for their identity (Greer
et al., 2012; Rafalski et al., 2012). However, it is not yet clear
how stem cells gain this metabolic signature and how they again
activate mitochondrial oxidative phosphorylation pathways dur-
ing differentiation.
The bioenergetics of pluripotent cells can vary depending on
their developmental stage. For example, mouse epiblasts stem
cells, which are believed to be at the same primed stage as
hESCs, are also highly glycolytic, whereas more naive mouse
ESCs are bivalent in their energy production, switching from gly-
colysis to mitochondrial respiration on demand (Zhou et al.,
2012). Human induced pluripotent stem cells (iPSCs) are usually
reprogrammed from somatic cells to a primed stage and are very
metabolically similar to hESCs (Panopoulos et al., 2012; Suhr
et al., 2010; Varum et al., 2011). Therefore, a metabolic switch
from oxidative to highly glycolytic needs to take place during
iPSC formation. Supporting this idea, the inhibition of glycolysis
reduces reprogramming efficiency, whereas stimulation of gly-
colytic activity enhances iPSC generation (Folmes et al., 2011;
Panopoulos et al., 2012; Zhu et al., 2010). How iPSCs establish
a Warburg-like metabolic phenotype during the reprogramming
process is largely unknown.
The dependency of stem cells on glycolysis to produce ATP
could be an adaptation to low-oxygen tensions in vivo, given
that hypoxia has appeared as a key feature of the stem cell niche
(Mohyeldin et al., 2010; Suda et al., 2011). Furthermore, low oxy-
gen levels are beneficial for embryonic stem cells (hESCs), adult
stem cells (Danet et al., 2003; Ezashi et al., 2005; Morrison et al.,
2000; Simsek et al., 2010; Studer et al., 2000), and cancer cells
(Axelson et al., 2005; Cabarcas et al., 2011; Mathieu et al.,
2011; Takubo and Suda, 2012). Cellular adaptation to hypoxic
conditions is mainly mediated through the activation of the oxy-
gen-sensitive transcription factors, hypoxia-inducible factors
(HIFs). In normoxia, HIF1a and HIF2a undergo prolyl hydroxyla-
tion, which leads to specific binding to the ubiquitin E3 ligase Von
Hippel-Lindau, polyubiquitination, and proteasomal degrada-
tion. However, HIF1a and HIF2a are stabilized in low oxygen
levels, dimerize with HIF1b, and control the transcription of
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metabolism (Pouysse´gur et al., 2006; Semenza, 2003). HIF1a is
expressed ubiquitously, whereas HIF2a expression is more tis-
sue restricted, and both factors have essential roles during de-
velopment (Compernolle et al., 2002; Iyer et al., 1998; Ryan
et al., 1998). Increasing evidence suggests that HIFs can activate
factors involved in pluripotency and regulate the stem cell phe-
notype in both normal and cancer cells (Ezashi et al., 2005,
Takubo and Suda, 2012, Covello et al., 2006; Mathieu et al.,
2011, 2013). In addition, hypoxia enhances the generation of
iPSCs (Yoshida et al., 2009). However the mode of function of
HIFs in the process is not fully understood. Given that HIF2a
has been shown to activate Oct4 and that HIF2a-deficient em-
bryos have severely reduced numbers of primordial germ cells
(Covello et al., 2006), it is believed to be the HIF family member
that regulates stem cells (Das et al., 2012; Franovic et al.,
2009; Heddleston et al., 2009; Li et al., 2009; Mohyeldin et al.,
2010). However, recent data indicate that HIF1a can also regu-
late stem cell properties (Takubo et al., 2010; Wang et al.,
2011). Therefore, it is important to dissect whether HIF1a and
HIF2a are involved in the acquisition of stem cell fate and, in par-
ticular, in themechanism underlying the hypoxia effect in reprog-
ramming and whether HIFs are responsible for the metabolic
shift during reprogramming.
We now show that both HIF2a and HIF1a are essential for the
metabolic changes required early for iPSC generation in hu-
mans. Furthermore, we show that HIF2a is required at early
stages, but is detrimental at later stages, of reprogramming.
HIF1a and HIF2a are sufficient to induce the stem-cell-specific
metabolic switch. However, prolonged HIF2a stabilization re-
presses reprogramming because of the upregulation of TNF-
related apoptosis-inducing ligand (TRAIL). These data reveal a
similarity between normal reprogramming and cancer progres-
sion; both require early metabolic switch induced by HIF1a
and HIF2a, and both are sensitive to the presence of TRAIL.
RESULTS
A Metabolic Switch Occurs Early during the
Reprogramming Process
Themetabolism of primed PSCs differs from the one observed in
naive PSCs or many differentiated cells (Varum et al., 2011; Zhou
et al., 2012). Primed stem cells show reduced mitochondrial ac-
tivity and rely on glycolysis, whereas differentiated cells produce
the majority of their ATP by mitochondrial oxidative phosphory-
lation. We used the reprogramming assay (Park et al., 2008;
Takahashi et al., 2007; Yu et al., 2007) to analyze the require-
ments for the acquisition of the metabolic state of primed
PSCs. Human fibroblasts were reprogrammed into an iPSC state
with the four reprogramming factors Oct4, Sox2, Lin28, and
Nanog (OSLN). To characterize the metabolic profiles of the
cells, we measured a metabolic parameter that mainly defines
the mitochondrial respiration levels, oxygen consumption rate
(OCR) under various conditions and treatments with Seahorse
Extracellular Flux Analyzer (Zhou et al., 2012). We treated the
cells with mitochondrial ATP synthase inhibitor, oligomycin,
and then a proton gradient discharger, carbonyl cyanide 4-(tri-
fluoromethoxy)phenylhydrazone (FCCP), in order to measure
the maximal turnover of the electron transport chain uncoupledfrom ATP synthesis. This analysis revealed the maximal mito-
chondrial reserve in the presence of glucose (Goldsby and Hey-
tler, 1963; Heytler, 1963). Fibroblasts showed significantly higher
levels of maximal respiratory capacity than hESCs and iPSCs
(Figure 1A; Figure S1A available online). These results, in line
with previous findings (Folmes et al., 2011; Prigione and Adjaye,
2010; Hansson et al., 2012), suggest that a switch from oxidative
to glycolytic metabolism occurs during the iPSC reprogramming
process. Furthermore, we examined the kinetics of the meta-
bolic switch by analyzing the OCR and extracellular acidification
rate of the cells at different time points of the reprogramming
process and found that the FCCP response after oligomycin
treatment was already significantly reduced at day 8 (D8) in re-
programming fibroblasts in comparison to control fibroblasts
(Figures 1B, 1C, and S1B–S1D). These data indicate that the
metabolic changes initiate early in the reprogramming process
and support the previous gene expression and proteomics anal-
ysis in mouse and human reprogramming (Folmes et al., 2011;
Prigione and Adjaye, 2010; Hansson et al., 2012).
Reprogramming Process Has Hypoxic Expression
Signature
To reveal the key metabolic genes involved in the transition, we
analyzed the gene expression profiles of reprogramming cells
and observed an increased expression of metabolic genes in
early (D12) and late (D30) time points of the entire fibroblast pop-
ulation exposed to reprogramming factors (Figures 1D, S1E, and
S1F and Table S1). The majority of the increased metabolic
genes during early reprogramming are hypoxia-responsive
genes (Figure 1E). We validated the early upregulation in reprog-
ramming process for ALDOC, ENO3, and PKM2 by quantitative
PCR (qPCR; Figure 1F). Given that the reprogramming experi-
ments were performed in normoxia, we tested whether perform-
ing the process in hypoxic conditions would be beneficial
(Figure 2A). Indeed, the reprogramming process is significantly
more efficient when performed in hypoxic conditions. In compar-
ison to 20% O2, both 2% and 5% O2 promote iPSC colony for-
mation in various cell lines, including IMR90, MRC5, and JM1
(Figures 2A, 2B, and S2A–S2C), confirming that hypoxia is ben-
eficial for iPSC induction (Yoshida et al., 2009). Using western
blot analysis, we showed that the two main hypoxia-responsive
factors, HIF1a and HIF2a, were stabilized in hypoxic reprogram-
ming process (Figures 2C, S2D, and S2E).
To test whether HIF1a andHIF2a are stabilized in the normoxic
(20% O2) reprogramming process, we analyzed multiple time
points in normal reprogramming (Figures 2D and S2F). Both
HIF1a and HIF2a proteins were stabilized during normoxic re-
programming (Figures 2C, 2D, and S2F). To test whether HIFs
are also transcriptionally active during the reprogramming in nor-
moxic oxygen environment, we introduced an HIF reporter that
contains six HIF-minimal binding sites in front of enhanced yel-
low fluorescent protein (eYFP) (Zhou et al., 2011) into the fibro-
blasts used for reprogramming assay (HFF1). This sensor has
shown to react to hypoxia and both HIF1a and HIF2a activity
(Zhou et al., 2011) (Figure S2G). By D7 of reprogramming, the
fluorescent signal had increased significantly, suggesting that
HIF1a and/or HIF2a are activated during the reprogramming
process (Figure 2E). However, when iPSC colonies were formed,
the signal was highly reduced, suggesting that the viral constructCell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc. 593
Figure 1. Metabolic Switch Occurs Early in Reprogramming Process
(A) Metabolic profile comparing hESCH7 and iPSCs to fibroblasts (IMR90). A representative trace of OCR changes is shown under mitochondrial stress protocol.
(B) IMR90 OSLN reprogramming cells have reduced OCR change at day 8 (D8) in response to FCCP following oligomycin treatment in comparison to the IMR90
fibroblasts.
(C) Kinetics of changes in oxidative metabolism in the entire IMR90 fibroblast population subjected to OSLN factors over the time course of reprogramming
process is shown. Significant change was first observed in D8 reprogramming cells, as shown by relative OCR changes after FCCP injection.
(D) Metabolic gene (Table S1) expression patterns display dynamic changes in early (D12) and late (D30, p = 0.001) reprogramming cells in comparison to IMR90
fibroblasts. In comparison to IMR90 fibroblasts, 74 metabolic genes show higher expression level in iPSCs and hESCs. Among those 74 genes, 27 are upre-
gulated in early (D12) reprogramming cells, whereas an additional 22 genes (total of 49) are upregulated in late (D30) reprogramming cells. Arrows indicate the
proportion of the 74 upregulated genes in each category.
(E) Microarray expression data are shown for metabolic genes that are upregulated more than 2-fold in early (OSLN D12) and late (OSLN D30) IMR90 re-
programming cells in comparison to the IMR90 fibroblasts. Hypoxia-responsive genes are highlighted in red.
(F) qRT-PCR validates the upregulation of some of these hypoxia-responsive genes in early reprogramming fibroblasts in comparison to control IMR90 fibro-
blasts. p values were calculated with a Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bars show SEM for at least three separate experiments.
See also Figure S1.
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viously (Takahashi et al., 2007; Xia et al., 2007; Yu et al., 2007).
HIF2a Is Required for the Metabolic Switch during Early
Reprogramming
To test whether HIF1a and/or HIF2a are required for the meta-
bolic switch observed during reprogramming, we used HIF1a
and HIF2a small hairpin RNA (shRNA) constructs that resulted
in a significant reduction of HIF1a and HIF2a protein levels, re-
spectively (Li et al., 2007) (Figures 2F, 2G, S3A, and S3B). Impor-
tantly, when either HIF1a or HIF2a were significantly reduced
starting from the initiation of the reprogramming process, at
the D8–D10 time point, the total OCR increase after FCCP
addition was abnormal. Although HIF1a shRNA effect in the
metabolic switch was not statistically significant, HIF2a knock-
down (KD) significantly blocked the process (Figures 2H–2K
and S3C). At D8, the reprogramming cells with HIF2aKD showed
a high OCR increase after FCCP treatment that was comparable
to fibroblasts. This starkly contrasts the highly reduced OCR de-
tected in the control reprogramming samples (Figures 2H–2K).
Furthermore, at the end of the reprogramming process, the num-
ber of iPSC colonies was also significantly reduced when HIF2a
was knocked down during the process in both normoxia and
hypoxia (Figures 2L and S3D). The iPSC colony formation was
also highly reduced when HIF1a was knocked down during the
process (Figure 2M). The reduction observed in iPSC induction
when HIF1a or HIF2awere knocked down was not due to signifi-
cantly reduced proliferation rates (Figure S3E). Furthermore, we
showed a reduction in the key metabolic hypoxia-responsive
genes in the reprogramming cells in which HIF1a or HIF2a was
knocked down (Figures 2N and S3F). Later in the reprogramming
process, an increase of small iPSC-like colonies was observed in
some of the HIF1a KD plates (Figures S3G–S3J). Altogether,
these data suggest that both HIF2a and HIF1a are required for
the metabolic switch that initiates early during the reprogram-
ming process and that this step is necessary for iPSC colony
formation.
Reprogramming Process Requires Controlled HIF2a
Activity
Because hypoxia is beneficial for reprogramming and HIF2a and
HIF1a are required for the process, we tested whether constitu-
tive stabilization of HIF1a and/or HIF2a would enhance iPSC
generation by overexpressing nondegradable forms of HIF1a
and HIF2a during reprogramming (Pro402, 564/Ala mutations
and Pro405,531/Ala mutations, respectively; Figures 3A and
S4A) (Yan et al., 2007). HIF1a overexpression (OE) during reprog-
ramming significantly increased the efficiency of iPSC colony
formation in normoxia as well as in hypoxia in IMR90 and
MRC5 fibroblast cell lines (Figures 3B–3D). However, surpris-
ingly prolonged stabilization of HIF2a significantly repressed
the reprogramming process in these conditions (Figures 3B–
3D), even in combination with HIF1a (Figures 3B and 3C). To
confirm that the morphologically and alkaline phosphatase
(AP)-staining-identified colonies consist of true pluripotent cells,
we stained all cells late in reprogramming processwith TRA-1-60
and quantified the positive cells by FACS analysis (Figures 3E–
3G and S4B–S4F). Importantly, similar to the morphological
analysis, TRA-1-60-positive cell number was increased whenHIF1a was stabilized but significantly reduced with HIF2a
stabilization (Figures 3F and 3G). As expected, TRA-1-60
FACS analysis also validated the loss-of-function data (Figures
3F, 3G, and 2M).
This difference in HIF1a OE and HIF2a OE effect on reprog-
ramming was not caused by differences in cell proliferation rates
(Figure S3E). The iPSC colonies derived from HIF1a-expressing
or control samples displayed hESC-like morphology, self-
renewal capacity, AP activity, and endogenous NANOG and
OCT4 mRNA expression (Figures 3H, 3I, and S4G). In addition,
their metabolic profile resembled the hESC metabolic profile,
as evident in the diminishedmitochondrial functional reserves in-
duced by FCCP following oligomycin treatment (Figure 3J). Cells
in these iPSC colonies were pluripotent, given that they had the
capacity to differentiate into all three germ layers, as indicated by
upregulation of mesoderm, endoderm, and ectodermmarkers in
embryoid body (EB) assays (Figure 3K) (Yu et al., 2007). Despite
several attempts, we were not able to maintain the few colonies
derived from the HIF2a-overexpressing cells. Altogether, these
data show that, although continuous and prolonged OE of
HIF1a is beneficial for reprogramming process, prolonged
HIF2a activation represses iPSC formation.
HIF2a Function at Different Stages of Reprogramming
We showed that a loss of HIF2a is detrimental for reprogramming
(Figures 2L and S3D). Surprisingly, although continuous HIF1a
activation is beneficial, continuous activation of HIF2a represses
iPSC induction, suggesting that the reprogramming process re-
quires tightly controlled HIF2a activity. To understand the timing
of HIF2a function in the process, instead of reducing HIF2a levels
from the beginning of reprogramming, we infected the cells with
shRNA against HIF2a in the middle of the reprogramming proc-
ess (D12) and measured the total number of iPSC colonies
formed late in the reprogramming process (D33; Figures 3L
and 3M). Interestingly, although HIF2a shRNA reduced iPSC col-
ony number significantly when introduced early (D0; Figure 2L),
no obvious defect was observed when HIF2a was knocked
down in the middle (D12) of the reprogramming process (Figures
3L and 3M). However, when the nondegradable form of HIF2a
was overexpressed in themiddle of the reprogramming process,
the iPSC colony number was significantly reduced (Figures 3L
and 3M). These data suggest that HIF2a is required early, but
not late, in iPSC induction. Furthermore, HIF2a needs to be
downregulated at the latter part of the reprogramming process,
given that constitutive activation of HIF2a late in the process
causes a significant repression of reprogramming.
HIF1a and HIF2a Overexpression Is Sufficient to Induce
Metabolic Changes
To analyze the mechanism of HIF1a and HIF2a action in somatic
cells, we expressed constitutively active HIF1a and HIF2a in
fibroblasts without the reprogramming factors. First, we vali-
dated the HIF1a and HIF2a activity by showing that in MRC5
fibroblast HIF1a and/or HIF2a OE results in the upregulation of
HIF target genes carbonic anhydrase 9 and miR-210 (Figures
4A and 4B). To test whether overactivation of HIF1a or HIF2a
could affect the metabolism of fibroblasts without the addition
of the reprogramming factors, we analyzed the maximum OCR
change after FCCP addition in these conditions. Importantly,Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc. 595
Figure 2. HIFs Are Required for the Metabolic Switch in Early Reprogramming
(A and B) Hypoxia (5% O2) enhances iPSC formation in three cell lines (JM1, IMR90, and MRC5). Colonies were counted at D21 after OSLN infection.
(C) Comparison of HIF1a and HIF2a protein levels in the reprogramming cells under normoxia (20% O2 at D9) and hypoxia (5% O2 at D7).
(D) HIF1a and HIF2a protein stabilization occurs in reprogramming fibroblasts (MRC5) under normoxia, as shown by western blots.
(E) HFF1 cells harboring a YFP hypoxia reporter show an increase of HIF activity during the course of reprogramming. Scale bars represent 200 mm.
(F and G) Western blots validate the KD of HIF1a and HIF2a with shRNA against HIF1a (F) and HIF2a (G), respectively, in HeLa cells.
(H and I) The changes in oxidative metabolism are shown for IMR90, IMR90 infected with OSLN, and IMR90 with OSLN+HIF1a shRNA or OSLN+HIF2a shRNA at
D8 of the reprogramming process with a representative trace of OCR under mitochondrial stress protocol (H) and relative OCR changes after FCCP injection (I).
(legend continued on next page)
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metabolic change was more prominent when both transcription
factors were activated simultaneously (Figure 4C). Furthermore,
we showed that the observed reduction onmitochondrial activity
was not due to the reduction of mitochondrial number by utilizing
mitochondrial DNA copy-number assay (Figure 4D). Because no
significant change in mitochondrial copy number was found in
HIF1a and HIF2a OE cells (Figure 4D), mitochondrial activity
regulated by gene expression, rather than mitochondrial num-
ber, is critical for the metabolic switch observed in fibroblasts.
Similarly, OCR reduction was accelerated when HIF1a or
HIF2a were overexpressed with OSLN during the reprogram-
ming assay (Figure 4E). Therefore, we tested whether HIF1a
and/or HIF2a OE would accelerate the increase in expression
patterns of metabolic genes observed during reprogramming
(Figure 1D). In order to examine the change in gene expression
that occurs at various stages of the reprogramming process
when HIF2a is OE during OSLN-induced reprogramming, we
performed amicroarray analysis (Figure S5A). First, we validated
the microarray data by showing that stem cell markers were
highly enriched in reprogramming cells and that hypoxia target
genes were upregulated in HIF2a OE reprogramming cells
(Figures S5B and S5C). Ourmicroarray analysis revealed that hy-
poxia target genes were enriched in HIF2a OE samples in com-
parison to fibroblasts (Figures S5D and S5E). Furthermore,
HIF2aOE andHIF1aOE accelerated themetabolic gene expres-
sion during the reprogramming process (Figure S5F). qPCR val-
idation revealed that many of the metabolic genes normally
upregulated late in reprogramming process were already upre-
gulated at the D12 time point because of HIF2a and HIF1a
overexpression (Figure 4F), suggesting hastened kinetics of the
metabolic switch in the reprogramming cells.
Among themetabolic genes upregulated late (D30) during nor-
mal reprogramming that were expressed earlier (D12) in HIF1a
and HIF2a OE cells was pyruvate dehydrogenase kinase 3
(PDK3; Figures 4F and S5F–S5H). PDK3, an enzyme that blocks
the conversion of pyruvate to acetyl-CoA, is significantly en-
riched in hESCs and hypoxic tumor cells (Mathieu et al., 2011;
Stadler et al., 2010). Unlike other PDKs, PDK3 is not inhibited
by excess pyruvate and therefore is considered a key regulator
for a switch from oxidative to glycolytic metabolism. We studied
the kinetics of PDK3 upregulation when HIF1a and/or HIF2a are
overexpressed during reprogramming by qRT-PCR. Although, in
control, an 8-fold increase in PDK3 expression was observed at
D30 of the reprogramming process, HIF1a and HIF2a acceler-
ated this process, given that upregulation of PDK3was observed
at D7 or D12 in reprogrammedMRC5 or IMR90 cells (Figures 4F,
4G, and S5H). Furthermore, we tested whether the inhibition of
PDK3 could suppress the HIF1a-induced increase in iPSC for-
mation. Using the chemical inhibitor Radicicol (Kato et al.,(J and K) The changes in oxidativemetabolism are shown forMRC5,MRC5 infecte
process with a representative trace of OCR under mitochondrial stress protocol (J
OSLN+HIF2a shRNA is significantly different from that in MRC5 infected with OS
(L) shRNA against HIF2a decreases iPSC colony formation in both 20% and 5%
(M) shRNA against HIF1a reduces the number of colonies observed at days 19–
(N) Expression of metabolic genes are reduced at D23 in IMR90 with OSLN+HIF1a
t test. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bars show SEM for at least three
See also Figures S2 and S3.2007), we showed that reduction of PDK3 activity reduced the
number of iPSC colonies in HIF1a-overexpressing reprogram-
ming cells as well as normal reprogramming cells (Figures 4H
and S5I), suggesting an important functional role for PDK3 in
HIF1a-induced increase in iPSC induction. However, given that
Radicicol did not fully eliminate iPSC induction, additional HIF
targets are probably involved in the process.
These data show that HIF1a and HIF2a together are sufficient
to induce the metabolic switch in fibroblasts. Similarly, HIF1a
and HIF2a stabilization in hypoxic cells is shown to be invariably
sequential (Keith et al., 2012; Zhou et al., 2011). These data sup-
port the hypothesis that HIF1a and HIF2a have a combinatorial,
perhaps sequential, role in the metabolic switch observed in
early iPSC induction. However, although HIF1a stabilization is
beneficial for the process, HIF2a stabilization late in the process
is surprisingly detrimental for iPSC induction.
HIF2a Inhibits Reprogramming through TRAIL
In accordance with the observation that HIF2a is required early,
but not late, in reprogramming, we also observed that both
MRC5 and IMR90 fibroblasts with HIF2a OE give rise to approx-
imately equal or larger number of precolonies in early time points
in comparison to the controls (before D14; Figures 5A, S6A, and
S6B), suggesting that HIF2a overexpression is beneficial during
the early phase of reprogramming. However, a significant
repression in colony formation and PDK3 expression was ob-
served in HIF2a overexpressing samples at later time points
(Figures 4G, 4H, 5A, and S6A). Similarly, HIF2a OE initiated
in the middle of reprogramming process (D12) dramatically
reduced iPSC colony formation (Figure 3M), suggesting that
HIF2a OE late during reprogramming is detrimental for iPSC
formation. Therefore, we examined the gene expression profiles
of HIF2a-overexpressing and control cells at D30 of the reprog-
ramming process in order to identify the key HIF2a target that
can repress iPSC formation.
As expected, the expression of stem cell markers was only en-
riched in the control samples, not HIF2a OE cells, validating the
lack of iPSC colonies (Figures 5B, 5C, S6C, and S6D). Impor-
tantly, we identified TRAIL as the most upregulated gene with
stabilized HIF2a at late stage of reprogramming in comparison
to controls (Figures 5D and S6E). This upregulation of TRAIL
was not observed early in reprogramming (Figure S6F) and
was specific for HIF2a OE, given that no effect in TRAIL expres-
sion was observed with stabilized HIF1a (Figure 5E). Further-
more, the significant upregulation of TRAIL was also observed
when HIF2a OE was induced late in reprogramming (D12; Fig-
ure 5F) and a trend of TRAIL downregulation was observed in
HIF2 KD late reprogramming samples (Figure S6G).
To analyze whether TRAIL expression was sufficient to re-
produce the repressive function of HIF2a, we administereddwith OSLN, andMRC5with OSLN+HIF2a shRNA at D8 of the reprogramming
) and relative OCR changes after FCCP injection (K). OCR change in MRC5 with
LN.
O2 in comparison to the control.
21.
shRNA in comparison to the control. p values were calculated with a Student’s
separate experiments.
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Figure 3. HIF1a and HIF2a Overexpression Have Opposite Effects on Reprogramming
(A) OE of nondegradable HIF1a and HIF2a was confirmed by western blot analysis in MRC5 6 days after OSLN infection.
(B–D) HIF1a OE promotes iPSC colony formation, whereas HIF2a OE inhibits colony formation in 5% (B) and 20% (C) O2 in MRC5 as well as 20% O2 in IMR90
(D; n = 7 independent experiments). Colonies were counted at D21 of reprogramming.
(E) Immunofluorescence microscopy shows that colonies counted at 21 days postinfection express the stem cell marker Tra-1-60. The scale bar
represents 250 mm.
(legend continued on next page)
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Figure 4. HIF1a and HIF2a Overexpression Are Sufficient to Induce a Metabolic Change
(A–D) In MRC5 fibroblasts infected with HIF1a OE alone, HIF2a OE alone, or HIF1a OE and HIF2a OE together. miR-210 expression was induced both in HIF1a-
and HIF2a-overexpressing cells (A), and carbonic anhydrase 9 (CA9) expression was induced only in HIF1a-overexpressing cells (B), confirming the functionality
of the overexpressed HIF proteins.
(C) Both HIF1a andHIF2a overexpression inMRC5 fibroblasts without OSLN factors induced glycolyticmetabolism similar to hESCH1. Shown are representative
Seahorse traces.
(D) Mitochondrial DNA copy number was not changed in HIF1a or HIF2a overexpressing MRC5 fibroblasts.
(E) Both HIF1a and HIF2a overexpression in reprogramming cells (IMR90+OSLN) at D8 resulted in a further decrease in the OCR after FFCP injection.
(F) qPCR validation of the expression level of metabolic genes that were upregulated by HIF1a or HIF2aOE in D12 sample in comparison to the control (blue and
red bars indicate the comparative expression in control as illustrated in Figure 1D).
(G) Kinetics of PDK3 mRNA level analyzed by qRT-PCR in IMR90 reprogramming cells is shown as the percentage of actin.
(H) Treatment of PDK3 inhibitor (PDKi) on HIF1a OE cells reduces colony formation in comparison to HIF1a OE cells in the vehicle control (EtOH). p values were
calculated with a Student’s t test. *p < 0.05; **p < 0.01. Scale bars show SEM for at least three separate experiments.
See also Figure S5.
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HIF1 and HIF2 in ReprogrammingTRAIL recombinant protein into the cell-culture media during
reprogramming process. Importantly, when 50 or 100 ng/ml
of TRAIL was administered to the reprogramming process,
fibroblasts continued dividing, but no iPSC colonies were
produced (Figures 5G and S6H–S6J), showing that TRAIL(F) Flow cytometry analysis of Tra-1-60 at D21 after OSLN infection in IMR90.
(G) Quantification of Tra-1-60-positive cells detected by flow cytometry at D21 of
and flow cytometry analysis of those triplicates are presented in Figures S4F and
(H–J) iPSC colonies reprogrammed from HIF1a OE IMR90 fibroblasts can self-
mitochondrial activity similar to hESCs (H7) that is different from the parental fib
(K) The differentiation abilities of both EV iPSC and HIF1a iPSC derived EBs are de
Brachyury and kinase insert domain receptor (KDR) are markers for mesoderm,
Tubb3 are markers for ectoderm.
(L) An experimental scheme is shown to test the requirement and specificity of H
(M) When infected at D12, HIF2a OE reduces colony formation, whereas HIF2a K
the EV-infected cells. p values were calculated with a Student’s t test. *p < 0.0
experiments.
See also Figure S4.mimics HIF2a OE phenotype by repressing the iPSC induction,
but not fibroblast viability. Furthermore, we showed that
the addition of TRAIL-neutralizing antibody (TRAIL Ab) on
HIF2a overexpressing cells was able to counteract HIF2a-
repressive function and rescue iPSC formation (Figures 5Hreprogramming. Scale bars show SEM for triplicate experiments. Colony count
S4D, respectively.
renew (H), express endogenous Oct4 and Nanog (I), and display a reduced
roblasts (IMR90; J). Scale bars represent 200 mm.
monstrated by qRT-PCR analysis of genes representative of three germ layers.
alpha-fetoprotein (AFP) and Sox17 are markers for endoderm, and Pax6 and
IF2a at the later stage of the iPSC reprogramming process.
D by shRNA shows no significant change in colony formation in comparison to
5; **p < 0.01; ***p < 0.001. Scale bars show SEM for at least three separate
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Figure 5. HIF2a Inhibits iPSC Formation
through TRAIL Activation
(A) Kinetics of iPSC colony formation in HIF2a OE
IMR90 fibroblasts (OSLN+HIF2a), showing an early
increase (before D14) but dramatic reduction of iPSC
colony formation in late time points in comparison to
the control (OSLN+EV).
(B and C) Stem cell markers are significantly upre-
gulated in the control (B), but not HIF2a OE (C), cells
during reprogramming.
(D) Microarray analysis reveals that TRAIL is the
most upregulated gene at D30 in HIF2a OE re-
programming cells in comparison to normal IMR90
reprogramming cells.
(E) qRT-PCR validation shows the high TRAIL mRNA
expression in HIF2a, but not HIF1a, OE reprogram-
ming cells in late time points (D30).
(F) TRAIL mRNA expression analyzed by qRT-PCR
increased at late time points (D30) in HIF2a OE cells
infected at D12 of the reprogramming process in
comparison to OSLN control cells.
(G) Administration of TRAIL during IMR90 re-
programming process (from D7) represses iPSC
formation but not fibroblast growth.
(H) Administration of TRAIL antibody on HIF2a-
overexpressing cells rescues iPSC formation in
IMR90. Colonies were counted at D21.
(I) Administration of TRAIL antibody (75 ng/ml) in the
normal reprogramming process (in IMR90) promotes
colony formation.
(J–L) In bothMRC5 (J) and IMR90 (K) reprogramming
cells, HIF2a OE represses PARP cleavage 5-fold (L)
in comparison to EV control and HIF1a OE cells
(three independent experiments).
(M) Western blots confirm that PARP cleavage
is reduced in reprogramming cells treated with
50 ng/ml TRAIL for 8 hr in comparison to the control.
(N) NF-kB target genes are visualized on a scatter
plot comparing HIF2a OE at D30 to EV for those that
are expressed 4-fold more in HIF2a OE cells.
(O) Quantification of XIAP expression by qRT-PCR
assay shows an increased XIAP expression in HIF2a
OE reprogramming cells in comparison to the EV at
D27. Importantly, such an increase is reduced in
HIF2a OE reprogramming cells treated with TRAIL
Ab. p values were calculated with a Student’s t test.
**p < 0.01 and ***p < 0.001. Scale bars show SEM for
at least three separate experiments.
See also Figure S6.
Cell Stem Cell
HIF1 and HIF2 in Reprogrammingand S6K–S6L). These data show that HIF2a exerts its
dominant repression at the late stage of reprogramming
through TRAIL.
TRAIL Effect in Reprogramming
To test whether TRAIL is normally expressed and has a repres-
sive effect during normal reprogramming, we added TRAIL Ab
during normal reprogramming (from D7 on) and counted the
iPSC colony number at D17 and D21 in the process. Importantly,
the colony number was significantly increased when endoge-
nous TRAIL was sequestered by TRAIL Ab (Figure 5I). The colo-
nies formed were able to undergo self-renewing division and
expressed endogenous Oct4 (Figure S6L). These data show600 Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc.that normal reprogramming generates low levels of endogenous
TRAIL, which has a repressive property on the reprogramming
process, and hence we proceeded to reveal the mechanism of
TRAIL action in the process.
TRAIL, by activating a specific set of receptors, can either in-
duce apoptosis through the caspase pathway or display an anti-
apoptotic effect, mostly through nuclear factor kB (NF-kB)
signaling (Me´rino et al., 2007; Walczak et al., 1999). We tested
whether HIF2a OE activates the caspase pathway through
TRAIL in the reprogramming cells by analyzing the level of
cleaved PARP, the cleavage target of active caspase 3. Instead
of caspase activation, we observed the repression of caspase,
as indicated by the significant reduction of cleaved PARP in
Figure 6. hESCs Bypass TRAIL Effect Due to Low Level of DcR2
(A and B) H1 hESCs can self-renew in the presence of TRAIL in culture.Morphologies (A) and percentage of survival (B) are shown for H1 cells with 50 or 100 ng/ml
TRAIL in culture for 7 days in comparison to control H1 cells.
(C) DcR2 mRNA expression is low in hESCs in comparison to reprogramming cells (IMR90 OSLN).
(D) TRAIL administration does not reduce PARP cleavage in H1 or H7.
(E) Models for the repressive action of prolonged HIF2a OE on reprogramming: TRAIL inhibits caspase activity by binding DcR2 and activating NF-kB (1) or
binding heteromeric complex of DcR2/DR5 (2). p values were calculated with a Student’s t test. ***p < 0.001. Scale bars show SEM for at least three separate
experiments.
See also Figure S7.
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(Figures 5J–5L). Furthermore, we tested whether exogenously
added TRAIL protein in the reprogramming system can affect
PARP cleavage and found that, 8 hr after TRAIL addition at
D17 of iPSC reprogramming, a reduction of PARP was also de-
tected (Figure 5M).
Given that reprogramming cells require active caspases (Li
et al., 2010), a reduction of caspase activity could be causal
for the lack of iPSC formation in cells constitutively overexpress-
ing HIF2a. Gene expression profiling data further revealed that
expression of NF-kB targets, and in particular cFLIP and XIAP,
inhibitors of caspase activation, are higher in HIF2a-overex-
pressing cells than the control (Figures 5N, 5O, and S6M and
Table S2), suggesting that TRAIL could induce antiapoptotic
activity instead of apoptotic signaling in reprogramming cells.
Importantly, TRAIL Ab significantly reduced the upregulation
of XIAP observed in HIF2a-overexpressing reprogramming cells
(Figure 5O).
hESCs Are Not Responsive to TRAIL
Because reprogramming cells are sensitive to TRAIL, we tested
TRAIL effect on pluripotent hESCs and iPSCs and found that,
surprisingly, these pluripotent cells can self-renew in the pres-
ence of TRAIL (Figures 6A, 6B, and S7A–S7D). Furthermore,
we found that this difference in TRAIL responsiveness correlated
with differential expression of TRAIL receptors. Although DR4
expression is 10-fold lower in reprogramming cells in compari-
son to hESCs, decoy receptor 2 (DcR2) expression is signifi-
cantly higher in fibroblasts (IMR90, 8% of actin; Figure S7E)
and reprogramming cells (1.3% of actin) than in hESCs or iPSCs
(0.05% of actin; Figures 6C and S7D). Previous data have shown
that DcR2, upon binding to TRAIL, can induce NF-kB signaling,
which imposes an inhibitory effect on caspase activation (Ehr-
hardt et al., 2003; Kim et al., 2002). A lower level of DcR2 in
hESCs might protect these cells from TRAIL-induced anticas-pase signals. Accordingly, in pluripotent cells cultured in the
presence of TRAIL for prolonged periods, we found that PARP
cleavage is not reduced in comparison to the controls (Figures
6D and S7A–S7C). These results show that TRAIL does not in-
hibit caspase activity in hESCs or iPSCs.
DISCUSSION
This study shows that reprogramming has distinct stages.
Although both HIF1a and HIF2a are required, HIF2a has a
stage-specific function in the process. HIF2a is essential in early,
but not late, in reprogramming. When stabilized, HIF2a is bene-
ficial in early reprogramming, but prolonged stabilization of
HIF2a, in contrast to HIF1a dramatically blocks iPSC formation.
We identified themechanism for prolonged HIF2a repressive ac-
tion in reprogramming. Through TRAIL, HIF2a inhibits caspase 3
activity, thereby repressing iPSC formation. Unlike reprogram-
ming cells, hESCs can self-renew in the presence of TRAIL in cul-
ture. This correlates with the low expression of DcR2 in hESCs.
Human embryonic stem cells are glycolytic (Panopoulos et al.,
2012; Prigione et al., 2010; Varum et al., 2011; Zhou et al., 2012),
and the reprogramming process undergoes and requires a met-
abolic switch from oxidative to glycolytic (Armstrong et al., 2010;
Panopoulos et al., 2011, 2012; Prigione et al., 2010, 2014; Varum
et al., 2011). This metabolic switch precedes the stem cell fate
marker expression (Folmes et al., 2011; Zhou et al., 2012).
Here, we show, by analyzing the metabolic flux, that the meta-
bolic switch begins early in the reprogramming process. These
data are in accordance with recent expression analysis of mouse
reprogramming cells and human reprogramming with cMyc as
one of the reprogramming factors (Polo et al., 2012; Prigione
et al., 2014). Interestingly, both HIF1a and HIF2a enhance and
are required for this switch, possibly through separate transcrip-
tional targets (Keith et al., 2012; Loboda et al., 2010). An interest-
ing question is whether themetabolic switch alone is sufficient toCell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc. 601
Figure 7. Model of HIF2a Stage-Dependent Role during the Reprog-
ramming Process
When oxidative fibroblasts are reprogrammed into glycolytic pluripotent cells,
metabolic switch from oxidative to glycolytic occurs. Our study shows that
such a metabolic switch takes place in early stage of the reprogramming
process, and HIF1a and HIF2a are essential for this metabolic change. In
contrast, constitutive HIF2a stabilization is detrimental for the reprogramming
process at the later stage, given that it promotes TRAIL expression, which
prevents reprogramming.
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HIF1 and HIF2 in Reprogramminginitiate the reprogramming process. We showed that prolonged
stabilization of HIF1a and HIF2a in fibroblasts is sufficient to
induce the metabolic switch from oxidative to highly glycolytic
observed in stem cells; however, it was not sufficient to induce
pluripotency. This could be due to the repressive effect of
HIF2a in iPSC induction through TRAIL. It will be important for
future research to test whether switching cell metabolism with
more tightly controlled HIFa expression, alone and/or in combi-
nation with other factors, could be another avenue for driving
somatic reprogramming.
Our findings show that HIF2a is required during the early iPSC
reprogramming process to promote the metabolic switch. How-
ever, prolonged stabilization of HIF2a represses iPSC formation
through TRAIL-induced inhibition of caspase 3 signaling. Previ-
ously, it was shown that the activation of apoptotic caspases
occurs during the reprogramming process, and their inhibition
prevents iPSC generation (Li et al., 2010). Now, we show that
HIF2a OE inhibits the caspase 3 activity induced by the re-
programming factors. We also show that HIF2a inhibits iPSC
formation through TRAIL. The binding of TRAIL to its cognate re-
ceptors DR4 and DR5 activates both apoptotic and nonapop-
totic signaling, whereas binding to its decoy receptor 2 (DcR2)
only activates antiapoptotic pathways (Degli-Esposti et al.,
1997; Sanlioglu et al., 2005). Interestingly, reprogramming cells
have a low level of DR4 but a high level of DcR2. In these cells,
TRAIL could activate DcR2, and thereby the NF-kB pathway
that can repress caspase activity (Ehrhardt et al., 2003; Kim
et al., 2002). Furthermore, given that reprogramming cells
require an active caspase pathway (Li et al., 2010), TRAIL-
dependent caspase inhibition could block iPSC formation (Fig-
ure 6E). Our finding that NF-kB targets, and in particular, the
antiapoptotic gene XIAP, are upregulated in HIF2a OE reprog-
ramming cells in comparison to controls (Figures 5N and 5O)
support this hypothesis. Alternatively, DcR2 could form a hetero-
meric complex with DR5 and inhibit caspase activation through
steric hindrance (Me´rino et al., 2006) (Figure 6E).We showed that
both fibroblasts and reprogramming cells have higher ex-
pression of DcR2 than hESCs, which may be due to low p53 ex-
pression in hESCs (Liu et al., 2005). Fibroblasts survive with
TRAIL-induced inhibition of the caspase pathway, whereas
fibroblasts in the process of becoming iPSCs are sensitive to602 Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc.TRAIL, indicating that similar DcR2 levels in two cell types can
lead to different outcomes because of cell-dependent responses
to the downstream pathway.
This study presents an example of a significant difference be-
tween HIF1a and HIF2a function in the same cellular process.
Our results suggest that HIF1a and HIF2amay play nonoverlap-
ping roles in iPSC reprogramming process: HIF1a and HIF2a are
essential for the metabolic switch and induction of pluripotency.
Additionally, prolonged stabilization of HIF1a increases iPSC in-
duction; however, surprisingly prolonged stabilization of HIF2a
significantly represses reprogramming through TRAIL activation
(Figure 7). A fine balance exists between the differential roles of
the two HIFa factors in early embryonic development, a period
when physiological hypoxia is critical for the formation and early
differentiation of both germline and somatic stem cells (Dunwoo-
die, 2009). Our findings in this study provide further evidence on
functional difference between HIF1a and HIF2a (Hu et al., 2007;
Husa et al., 2010). Reprogramming assays can be used in the
future to reveal how structural differences between the two
HIFa factors lead to their diverse functional outcomes.
Along with previous studies, this study shows that TRAIL does
not induce death in hESCs, cancer stem cells or adult stem cells
(Kruyt and Schuringa, 2010). However, TRAIL is detrimental for
cancer cells (Me´rino et al., 2007; Walczak et al., 1999). Our study
now reveals that TRAIL also represses the iPSC reprogramming
process. These data suggest a similar mechanism in response to
TRAIL in cancer cells and reprogramming cells. In general, the
results suggest that cells undergoing reprogramming process
may have similar characteristics to the cells undergoing progres-
sion toward aggressive tumor cell, allowing us to propose that
cancer progression is a slow reprogramming process. First, can-
cer cells and cells under reprogramming (iPSC induction) both
change their metabolism from oxidative to highly glycolytic early
during the process. Second, HIFs regulate the switch in both cell
types. Third, cancer cells and reprogramming cells are sensitive
to TRAIL, whereas cancer stem cells and PSCs are resistant to
TRAIL. These similarities between cancer cells and reprogram-
ming cells may allow us to utilize somatic cell reprogramming
process in the future as a model for understanding mechanisms
and events involved in the cancer progression and to learn from
our current knowledge in cancer progression in order to facilitate
understanding of the acquisition of pluripotency.
EXPERIMENTAL PROCEDURES
Cell Culture and Reprogramming
hESCs and isolated iPSCs were maintained as previously described (Ware
et al., 2006). Reprogramming of human fibroblasts (MRC5, IMR90, and
HFF1) was carried out with OSLN lentiviruses (generated from Addgene con-
structs #21162 and #21163) (Yu et al., 2009). In order to examine hypoxia effect
on iPSC formation, cells were cultured under 2% or 5% of O2 from D7 postin-
fection. The number of iPSC colonies was defined as the number of AP-,
Oct4-GFP-, and/or Tra-1-60-positive colonies. See details in the Supplemen-
tal Experimental Procedures.
Overexpression and Inhibition of HIF1a or HIF2a during
Reprogramming
Retroviruses expressing nondegradable HIF1a or HIF2a (Addgene constructs
#19005 and #19006) (Yan et al., 2007) were infected along with OSLN on D0.
An empty vector (EV) construct was used as a control. In order to examine
the role of HIF2a in the later stage of the reprogramming process, OSLN
Cell Stem Cell
HIF1 and HIF2 in Reprogrammingreprogramming cells were infected with HIF2a retrovirus at D12. HIF1a and
HIF2a KD were obtained with shRNA constructs (shHIF1a in comparison
to shRNA scramble control; Addgene plasmids #22131/shHIF2#2 and
#22132/shHIF2#3) (Nemetski and Gardner, 2007; Li et al., 2007). HIF1a and
HIF2a OE and KD were validated by western blot analysis.
iPSC Formation with Recombinant TRAIL, TRAIL Ab, or PDK3
Inhibitor Administration
During the iPSC reprogramming process, human TRAIL recombinant protein
(R&D Systems; 50 or 100 ng/ml), human TRAIL polyclonal antibody (R&D
Systems; 75 or 50 ng/ml), or PDK3 inhibitor Radicicol (Sigma-Aldrich,
36.5 ng/ml) (Kato et al., 2007) were added to OSLN-infected fibroblasts on
D7 and every other day along with media change.
Western Blot Analysis, qRT-PCR Analysis, and Mitochondrial DNA
Copy-Number Measurement
Standard protocols were used. See details in the Supplemental Experimental
Procedures. Primers used in our study are listed in Table S3.
Whole-Genome-Wide Microarray Analysis
Total RNA isolated from IMR90 and MRC5 reprogramming cells infected with
HIF2a OE virus or EV control at days 12 and 30 were used in the microarray
analysis. RNA qualification, Agilent microarray labeling, hybridization, and
scanning were performed in microarray facility at the Institute for Systems
Biology. Any intensity-dependent biases were removed in the data with the
normalize.qspline function in the affy Bioconductor package.
OCR Measurement with Seahorse Cellular Flux Assays
Mito Stress and Glucose Stress assays were performed on fibroblasts and re-
programming fibroblasts (infected by OSLN) with the Seahorse XF96 Extracel-
lular Flux Analyzer. The OCR values were further normalized to the number of
cells and quantified by the Hoechst staining (HO33342; Sigma-Aldrich). See
the Supplemental Experimental Procedures for details.
In Vivo Detection of HIF Activity with eYFP Reporting System
In order to test the level of HIF transcriptional activity during reprogramming,
fibroblasts were infected with HIF reporter HBR-6U lentivirus (Zhou et al.,
2011) before undergoing normal reprogramming assay in normoxia.
Statistical Analysis
Throughout the paper, p values were calculated with Student’s t tests. *p <
0.05, **p < 0.01, ***p < 0.001. Scale bars show the SEM of at least three
separate experiments.
ACCESSION NUMBER
Microarray data have been deposited to the NCBI Gene Expression Omnibus
under accession number GSE54898.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2014.02.012.
ACKNOWLEDGMENTS
We thank Drs. Ware, Hockenbery, and Horwitz and members of the H.R.-B.
laboratory for helpful discussions throughout this work. We thank Dr. Stadler
for work early in the project. We thank Michael Choi and Timothy Dosey for
technical help. We thank Pamela Troisch from Institute for Systems Biology
for themicroarray gene expression service and Dr. Mecham fromSage Bionet-
works for some of the statistical analysis on microarray data. We thank
Dr. Gardner for providing the scramble shRNA and shRNA against HIF1a.
We also thank members of Tom & Sue Ellison Stem Cell Core for help on
iPSC reprogramming procedures and cell cultures. This work was supported
by fellowships from the American Heart Association (to J.M., W.Z., andY.X.), a Tietze Award (to K.T.K.), and grants from the National Institutes
of Health (R01GM097372, R01GM083867, and R01GM083867-02S2 to
H.R.-B., U01HL100395 to Z.A. and R.T.M., and P01GM081619 to R.T.M.
and H.R.-B.).
Received: June 3, 2013
Revised: October 4, 2013
Accepted: February 21, 2014
Published: March 20, 2014
REFERENCES
Armstrong, L., Tilgner, K., Saretzki, G., Atkinson, S.P., Stojkovic, M., Moreno,
R., Przyborski, S., and Lako, M. (2010). Human induced pluripotent stem cell
lines show stress defense mechanisms and mitochondrial regulation similar
to those of human embryonic stem cells. Stem Cells 28, 661–673.
Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G., and Pa˚hlman, S.
(2005). Hypoxia-induced dedifferentiation of tumor cells—a mechanism be-
hind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev.
Biol. 16, 554–563.
Cabarcas, S.M., Mathews, L.A., and Farrar, W.L. (2011). The cancer stem cell
niche—there goes the neighborhood? Int. J. Cancer 129, 2315–2327.
Cairns, R.A., Harris, I.S., and Mak, T.W. (2011). Regulation of cancer cell
metabolism. Nat. Rev. Cancer 11, 85–95.
Compernolle, V., Brusselmans, K., Acker, T., Hoet, P., Tjwa, M., Beck, H.,
Plaisance, S., Dor, Y., Keshet, E., Lupu, F., et al. (2002). Loss of HIF-2alpha
and inhibition of VEGF impair fetal lung maturation, whereas treatment with
VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8,
702–710.
Covello, K.L., Kehler, J., Yu, H., Gordan, J.D., Arsham, A.M., Hu, C.J.,
Labosky, P.A., Simon, M.C., and Keith, B. (2006). HIF-2alpha regulates
Oct-4: effects of hypoxia on stem cell function, embryonic development,
and tumor growth. Genes Dev. 20, 557–570.
Danet, G.H., Pan, Y., Luongo, J.L., Bonnet, D.A., and Simon, M.C. (2003).
Expansion of human SCID-repopulating cells under hypoxic conditions.
J. Clin. Invest. 112, 126–135.
Das, B., Bayat-Mokhtari, R., Tsui, M., Lotfi, S., Tsuchida, R., Felsher, D.W., and
Yeger, H. (2012). HIF-2a suppresses p53 to enhance the stemness and regen-
erative potential of human embryonic stem cells. Stem Cells 30, 1685–1695.
Degli-Esposti, M.A., Dougall, W.C., Smolak, P.J., Waugh, J.Y., Smith, C.A.,
and Goodwin, R.G. (1997). The novel receptor TRAIL-R4 induces NF-
kappaB and protects against TRAIL-mediated apoptosis, yet retains an in-
complete death domain. Immunity 7, 813–820.
Dunwoodie, S.L. (2009). The role of hypoxia in development of the Mammalian
embryo. Dev. Cell 17, 755–773.
Ehrhardt, H., Fulda, S., Schmid, I., Hiscott, J., Debatin, K.M., and Jeremias, I.
(2003). TRAIL induced survival and proliferation in cancer cells resistant
towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22,
3842–3852.
Ezashi, T., Das, P., and Roberts, R.M. (2005). Low O2 tensions and the
prevention of differentiation of hES cells. Proc. Natl. Acad. Sci. USA 102,
4783–4788.
Folmes, C.D., Nelson, T.J., Martinez-Fernandez, A., Arrell, D.K., Lindor, J.Z.,
Dzeja, P.P., Ikeda, Y., Perez-Terzic, C., and Terzic, A. (2011). Somatic oxida-
tive bioenergetics transitions into pluripotency-dependent glycolysis to facili-
tate nuclear reprogramming. Cell Metab. 14, 264–271.
Franovic, A., Holterman, C.E., Payette, J., and Lee, S. (2009). Human cancers
converge at the HIF-2alpha oncogenic axis. Proc. Natl. Acad. Sci. USA 106,
21306–21311.
Goldsby, R.A., and Heytler, P.G. (1963). Uncoupling of Oxidative
Phosphorylation by Carbonyl Cyanide Phenylhydrazones. Ii. Effects of
Carbonyl Cyanide M-Chlorophenylhydrazone on Mitochondrial Respiration.
Biochemistry 2, 1142–1147.
Greer, S.N., Metcalf, J.L., Wang, Y., and Ohh, M. (2012). The updated biology
of hypoxia-inducible factor. EMBO J. 31, 2448–2460.Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc. 603
Cell Stem Cell
HIF1 and HIF2 in ReprogrammingHansson, J., Rafiee, M.R., Reiland, S., Polo, J.M., Gehring, J., Okawa, S.,
Huber, W., Hochedlinger, K., and Krijgsveld, J. (2012). Highly coordinated pro-
teome dynamics during reprogramming of somatic cells to pluripotency. Cell
Rep 2, 1579–1592.
Heddleston, J.M., Li, Z., McLendon, R.E., Hjelmeland, A.B., and Rich, J.N.
(2009). The hypoxic microenvironment maintains glioblastoma stem cells
and promotes reprogramming towards a cancer stem cell phenotype. Cell
Cycle 8, 3274–3284.
Heytler, P.G. (1963). uncoupling of oxidative phosphorylation by carbonyl
cyanide phenylhydrazones. I. Some characteristics of m-Cl-CCP action on
mitochondria and chloroplasts. Biochemistry 2, 357–361.
Hu, C.J., Sataur, A., Wang, L., Chen, H., and Simon, M.C. (2007). The
N-terminal transactivation domain confers target gene specificity of hypoxia-
inducible factors HIF-1alpha and HIF-2alpha. Mol. Biol. Cell 18, 4528–4542.
Husa, M., Liu-Bryan, R., and Terkeltaub, R. (2010). Shifting HIFs in osteoarthri-
tis. Nat. Med. 16, 641–644.
Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H.,
Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., and Semenza, G.L.
(1998). Cellular and developmental control of O2 homeostasis by hypoxia-in-
ducible factor 1 alpha. Genes Dev. 12, 149–162.
Kato, M., Li, J., Chuang, J.L., and Chuang, D.T. (2007). Distinct structural
mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by
AZD7545, dichloroacetate, and radicicol. Structure 15, 992–1004.
Keith, B., Johnson, R.S., and Simon, M.C. (2012). HIF1a and HIF2a: sibling
rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9–22.
Kim, Y.S., Schwabe, R.F., Qian, T., Lemasters, J.J., and Brenner, D.A. (2002).
TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochon-
drial permeability transition in human hepatoma cells. Hepatology 36, 1498–
1508.
Kruyt, F.A., and Schuringa, J.J. (2010). Apoptosis and cancer stem cells:
Implications for apoptosis targeted therapy. Biochem. Pharmacol. 80,
423–430.
Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y.A., Olumi, A.F., Mao, M.,
Bartz, S., and Kaelin, W.G., Jr. (2007). Hypoxia-inducible factor linked to differ-
ential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol.
Cell. Biol. 27, 5381–5392.
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao,
Y., Lathia, J., McLendon, R.E., et al. (2009). Hypoxia-inducible factors regulate
tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501–513.
Li, F., He, Z., Shen, J., Huang, Q., Li, W., Liu, X., He, Y., Wolf, F., and Li, C.Y.
(2010). Apoptotic caspases regulate induction of iPSCs from human fibro-
blasts. Cell Stem Cell 7, 508–520.
Liu, X., Yue, P., Khuri, F.R., and Sun, S.Y. (2005). Decoy receptor 2 (DcR2) is a
p53 target gene and regulates chemosensitivity. Cancer Res. 65, 9169–9175.
Loboda, A., Jozkowicz, A., and Dulak, J. (2010). HIF-1 and HIF-2 transcription
factors—similar but not identical. Mol. Cells 29, 435–442.
Mathieu, J., Zhang, Z., Zhou, W., Wang, A.J., Heddleston, J.M., Pinna, C.M.,
Hubaud, A., Stadler, B., Choi, M., Bar, M., et al. (2011). HIF induces human em-
bryonic stem cell markers in cancer cells. Cancer Res. 71, 4640–4652.
Mathieu, J., Zhang, Z., Nelson, A., Lamba, D.A., Reh, T.A., Ware, C., and
Ruohola-Baker, H. (2013). Hypoxia induces re-entry of committed cells into
pluripotency. Stem Cells 31, 1737–1748.
Me´rino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., and Micheau, O.
(2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy
receptors 1 and 2. Mol. Cell. Biol. 26, 7046–7055.
Me´rino, D., Lalaoui, N., Morizot, A., Solary, E., andMicheau, O. (2007). TRAIL in
cancer therapy: present and future challenges. Expert Opin. Ther. Targets 11,
1299–1314.
Mohyeldin, A., Garzo´n-Muvdi, T., andQuin˜ones-Hinojosa, A. (2010). Oxygen in
stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7,
150–161.
Morrison, S.J., Csete, M., Groves, A.K., Melega, W., Wold, B., and Anderson,
D.J. (2000). Culture in reduced levels of oxygen promotes clonogenic sympa-604 Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc.thoadrenal differentiation by isolated neural crest stem cells. J. Neurosci. 20,
7370–7376.
Nemetski, S.M., and Gardner, L.B. (2007). Hypoxic regulation of Id-1 and ac-
tivation of the unfolded protein response are aberrant in neuroblastoma.
J. Biol. Chem. 282, 240–248.
Panopoulos, A.D., Ruiz, S., Yi, F., Herrerı´as, A., Batchelder, E.M., and Izpisua
Belmonte, J.C. (2011). Rapid and highly efficient generation of induced pluri-
potent stem cells from human umbilical vein endothelial cells. PLoS ONE 6,
e19743.
Panopoulos, A.D., Yanes, O., Ruiz, S., Kida, Y.S., Diep, D., Tautenhahn, R.,
Herrerı´as, A., Batchelder, E.M., Plongthongkum, N., Lutz, M., et al. (2012).
The metabolome of induced pluripotent stem cells reveals metabolic changes
occurring in somatic cell reprogramming. Cell Res. 22, 168–177.
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H.,
Lensch, M.W., and Daley, G.Q. (2008). Reprogramming of human somatic
cells to pluripotency with defined factors. Nature 451, 141–146.
Polo, J.M., Anderssen, E., Walsh, R.M., Schwarz, B.A., Nefzger, C.M., Lim,
S.M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., et al. (2012). A molec-
ular roadmap of reprogramming somatic cells into iPS cells. Cell 151, 1617–
1632.
Pouysse´gur, J., Dayan, F., andMazure, N.M. (2006). Hypoxia signalling in can-
cer and approaches to enforce tumour regression. Nature 441, 437–443.
Prigione, A., and Adjaye, J. (2010). Modulation ofmitochondrial biogenesis and
bioenergetic metabolism upon in vitro and in vivo differentiation of human ES
and iPS cells. Int. J. Dev. Biol. 54, 1729–1741.
Prigione, A., Fauler, B., Lurz, R., Lehrach, H., and Adjaye, J. (2010). The
senescence-related mitochondrial/oxidative stress pathway is repressed in
human induced pluripotent stem cells. Stem Cells 28, 721–733.
Prigione, A., Rohwer, N., Hoffmann, S., Mlody, B., Drews, K., Bukowiecki, R.,
Blu¨mlein, K., Wanker, E.E., Ralser, M., Cramer, T., and Adjaye, J. (2014). HIF1a
modulates cell fate reprogramming through early glycolytic shift and upregu-
lation of PDK1-3 and PKM2. Stem Cells 32, 364–376.
Rafalski, V.A., Mancini, E., and Brunet, A. (2012). Energy metabolism and
energy-sensing pathways in mammalian embryonic and adult stem cell fate.
J. Cell Sci. 125, 5597–5608.
Ryan, H.E., Lo, J., and Johnson, R.S. (1998). HIF-1 alpha is required for solid
tumor formation and embryonic vascularization. EMBO J. 17, 3005–3015.
Sanlioglu, A.D., Dirice, E., Aydin, C., Erin, N., Koksoy, S., and Sanlioglu, S.
(2005). Surface TRAIL decoy receptor-4 expression is correlated with TRAIL
resistance in MCF7 breast cancer cells. BMC Cancer 5, 54.
Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3,
721–732.
Simsek, T., Kocabas, F., Zheng, J., Deberardinis, R.J., Mahmoud, A.I., Olson,
E.N., Schneider, J.W., Zhang, C.C., and Sadek, H.A. (2010). The distinct met-
abolic profile of hematopoietic stem cells reflects their location in a hypoxic
niche. Cell Stem Cell 7, 380–390.
Stadler, B., Ivanovska, I., Mehta, K., Song, S., Nelson, A., Tan, Y., Mathieu, J.,
Darby, C., Blau, C.A., Ware, C., et al. (2010). Characterization of microRNAs
involved in embryonic stem cell states. Stem Cells Dev. 19, 935–950.
Studer, L., Csete, M., Lee, S.H., Kabbani, N., Walikonis, J., Wold, B., and
McKay, R. (2000). Enhanced proliferation, survival, and dopaminergic differen-
tiation of CNS precursors in lowered oxygen. J. Neurosci. 20, 7377–7383.
Suda, T., Takubo, K., and Semenza, G.L. (2011). Metabolic regulation of hem-
atopoietic stem cells in the hypoxic niche. Cell Stem Cell 9, 298–310.
Suhr, S.T., Chang, E.A., Tjong, J., Alcasid, N., Perkins, G.A., Goissis, M.D.,
Ellisman, M.H., Perez, G.I., and Cibelli, J.B. (2010). Mitochondrial rejuvenation
after induced pluripotency. PLoS ONE 5, e14095.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Takubo, K., and Suda, T. (2012). Roles of the hypoxia response system in hem-
atopoietic and leukemic stem cells. Int. J. Hematol. 95, 478–483.
Cell Stem Cell
HIF1 and HIF2 in ReprogrammingTakubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y.,
Shima, H., Johnson, R.S., Hirao, A., Suematsu, M., and Suda, T. (2010).
Regulation of the HIF-1alpha level is essential for hematopoietic stem cells.
Cell Stem Cell 7, 391–402.
Varum, S., Rodrigues, A.S., Moura, M.B., Momcilovic, O., Easley, C.A., 4th,
Ramalho-Santos, J., Van Houten, B., and Schatten, G. (2011). Energy metab-
olism in human pluripotent stem cells and their differentiated counterparts.
PLoS ONE 6, e20914.
Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin,W.,
Jones, J., Woodward, A., Le, T., et al. (1999). Tumoricidal activity of tumor
necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5,
157–163.
Wang, Y., Liu, Y., Malek, S.N., Zheng, P., and Liu, Y. (2011). Targeting HIF1a
eliminates cancer stem cells in hematological malignancies. Cell Stem Cell
8, 399–411.
Ware, C.B., Nelson, A.M., and Blau, C.A. (2006). A comparison of NIH-
approved human ESC lines. Stem Cells 24, 2677–2684.
Xia, X., Zhang, Y., Zieth, C.R., and Zhang, S.C. (2007). Transgenes delivered by
lentiviral vector are suppressed in human embryonic stem cells in a promoter-
dependent manner. Stem Cells Dev. 16, 167–176.
Yan, Q., Bartz, S., Mao, M., Li, L., and Kaelin, W.G., Jr. (2007). The hypoxia-
inducible factor 2alpha N-terminal and C-terminal transactivation domains
cooperate to promote renal tumorigenesis in vivo. Mol. Cell. Biol. 27, 2092–
2102.
Yanes, O., Clark, J., Wong, D.M., Patti, G.J., Sa´nchez-Ruiz, A., Benton, H.P.,
Trauger, S.A., Desponts, C., Ding, S., and Siuzdak, G. (2010). Metabolic oxida-
tion regulates embryonic stem cell differentiation. Nat. Chem. Biol. 6, 411–417.Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., and Yamanaka, S. (2009).
Hypoxia enhances the generation of induced pluripotent stem cells. Cell
Stem Cell 5, 237–241.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L.,
Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced
pluripotent stem cell lines derived from human somatic cells. Science 318,
1917–1920.
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I., and Thomson,
J.A. (2009). Human induced pluripotent stem cells free of vector and transgene
sequences. Science 324, 797–801.
Zhang, J., Khvorostov, I., Hong, J.S., Oktay, Y., Vergnes, L., Nuebel, E.,
Wahjudi, P.N., Setoguchi, K., Wang, G., Do, A., et al. (2011). UCP2 regulates
energy metabolism and differentiation potential of human pluripotent stem
cells. EMBO J. 30, 4860–4873.
Zhou, W., Dosey, T.L., Biechele, T., Moon, R.T., Horwitz, M.S., and Ruohola-
Baker, H. (2011). Assessment of hypoxia inducible factor levels in cancer cell
lines upon hypoxic induction using a novel reporter construct. PLoS ONE 6,
e27460.
Zhou, W., Choi, M., Margineantu, D., Margaretha, L., Hesson, J.,
Cavanaugh, C., Blau, C.A., Horwitz, M.S., Hockenbery, D., Ware, C., and
Ruohola-Baker, H. (2012). HIF1a induced switch from bivalent to exclusively
glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J. 31,
2103–2116.
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K.,
and Ding, S. (2010). Reprogramming of human primary somatic cells by OCT4
and chemical compounds. Cell Stem Cell 7, 651–655.Cell Stem Cell 14, 592–605, May 1, 2014 ª2014 Elsevier Inc. 605
